Access the world's leading financial data and tools

Subscribe for $2
Overview
Profile

VIVA Biotech Holdings stock

1873.HK
KYG9390W1015
A2PH5Q

Price

0.85
Today +/-
-0.00
Today %
-4.10 %
P

VIVA Biotech Holdings stock price

%
Weekly
Details

Price

ⓘ

Overview

The Quote Chart provides detailed and dynamic insights into the VIVA Biotech Holdings stock's performance, showcasing daily, weekly, or monthly aggregated quotes. Users can switch between different time frames to analyze the stock's progression meticulously and make informed investment decisions.

Intraday Feature

The intraday feature provides real-time data, allowing investors to view the VIVA Biotech Holdings stock’s price fluctuations within the trading day, facilitating timely and strategic investment decisions.

Total Return and Relative Price Change

View the total return of the VIVA Biotech Holdings stock to gauge its profitability over time. The relative price change, based on the first quote available in the selected timeframe, offers insights into the stock’s performance, assisting in evaluating its investment potential.

Interpretation and Investment

Utilize the comprehensive data presented in the Quote Chart to analyze VIVA Biotech Holdings's market trends, price movements, and potential returns. Make informed investment choices by comparing different time frames and evaluating intraday data for optimized portfolio management.

VIVA Biotech Holdings Stock Price History

DateVIVA Biotech Holdings Price
11/1/20240.85 undefined
10/31/20240.89 undefined
10/30/20240.88 undefined
10/29/20240.91 undefined
10/28/20240.94 undefined
10/25/20240.86 undefined
10/24/20240.83 undefined
10/23/20240.84 undefined
10/22/20240.85 undefined
10/21/20240.84 undefined
10/18/20240.81 undefined
10/17/20240.80 undefined
10/16/20240.77 undefined
10/15/20240.82 undefined
10/14/20240.85 undefined
10/10/20240.88 undefined
10/9/20240.88 undefined
10/8/20240.97 undefined
10/7/20241.08 undefined
10/4/20240.98 undefined

VIVA Biotech Holdings Revenue, EBIT, Net Income

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details

Revenue, EBIT and Profit

ⓘ

Understanding Revenue, EBIT, and Income

Gain insights into VIVA Biotech Holdings, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by VIVA Biotech Holdings from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects VIVA Biotech Holdings’s net earnings, an ultimate measure of its financial health and profitability.

Yearly Analysis and Comparisons

Observe the yearly bars to understand the annual performance and growth of VIVA Biotech Holdings. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.

Utilizing Expectations for Investment

The expected values for the forthcoming years offer investors a glimpse into VIVA Biotech Holdings’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.

Investment Insights

Leveraging the comparison between Revenue and EBIT helps in assessing VIVA Biotech Holdings’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on VIVA Biotech Holdings’s growth potential.

VIVA Biotech Holdings Revenue, EBIT and net profit per share

DateVIVA Biotech Holdings RevenueVIVA Biotech Holdings EBITVIVA Biotech Holdings Net Income
2025e3.43 B undefined487.27 M undefined519.94 M undefined
2024e3.03 B undefined401.91 M undefined439.11 M undefined
20232.16 B undefined234.71 M undefined-116.11 M undefined
20222.38 B undefined295.38 M undefined-528.48 M undefined
20212.1 B undefined260.11 M undefined287.55 M undefined
2020696.96 M undefined89.5 M undefined-386.88 M undefined
2019323.06 M undefined60.14 M undefined265.87 M undefined
2018210.03 M undefined54.56 M undefined90.55 M undefined
2017148.25 M undefined57.43 M undefined76.26 M undefined
201696.49 M undefined29.41 M undefined24.47 M undefined

VIVA Biotech Holdings Income Statement, Balance Sheet, Cash Flow Statement

  • Simple

  • Expanded

  • Income Statement

  • Balance Sheet

  • Cashflow

 
REVENUE (B)REVENUE GROWTH (%)GROSS MARGIN (%)GROSS INCOME (M)EBIT (M)EBIT MARGIN (%)NET INCOME (M)NET INCOME GROWTH (%)SHARES (B)DOCUMENTS
201620172018201920202021202220232024e2025e
0.10.150.210.320.72.12.382.163.033.43
-54.1741.8953.81115.48202.3013.07-9.4240.4613.25
56.2558.1150.0047.9943.6830.8934.2634.25--
548610515530465081573800
2957546089260295234401487
30.2138.5125.7118.5812.7912.3612.4010.8613.2514.21
247690265-386287-528-116439519
-216.6718.42194.44-245.66-174.35-283.97-78.03-478.4518.22
1.151.161.191.481.571.971.921.9400
----------
Details

Keystats

ⓘ

Revenue and Growth

The VIVA Biotech Holdings Revenue and Revenue Growth are pivotal to understanding the company's financial health and operational efficiency. A consistent increase in revenue indicates a company’s ability to effectively market and sell its products or services, while the revenue growth percentage offers insights into the pace at which the company is expanding over the years.

Gross Margin

The Gross Margin is a crucial metric that showcases the percentage of revenue exceeding the cost of goods sold (COGS). A higher gross margin is indicative of a company’s efficiency in controlling its production costs, thereby promising potential profitability and financial stability.

EBIT and EBIT Margin

EBIT (Earnings Before Interest and Taxes) and EBIT Margin offer deep insights into a company’s profitability, excluding the impacts of interest and taxes. Investors often assess these metrics to gauge the operational efficiency and inherent profitability of a business, separate from its financial structure and tax environment.

Income and Growth

Net Income and its subsequent growth are quintessential for investors looking to understand a company’s profitability. Consistent income growth underscores a company’s ability to enhance its profitability over time, reflecting operational efficiency, strategic competitiveness, and financial health.

Shares Outstanding

Shares outstanding refer to the total number of shares a company has issued. It's instrumental in calculating key metrics like Earnings Per Share (EPS) which is pivotal for investors to evaluate a company’s profitability on a per-share basis, offering a more granular view of financial health and valuation.

Interpreting Year to Year Comparison

Comparing yearly data allows investors to identify trends, assess the company’s growth, and anticipate potential future performance. Analyzing how metrics like revenue, income, and margins change year over year can provide valuable insights into the company’s operational efficiency, competitiveness, and overall financial health.

Expectations and Predictions

Investors often juxtapose the current and past financial data with the market’s expectations. This comparison aids in assessing whether the VIVA Biotech Holdings is performing as anticipated, underperforming or outperforming the market predictions, providing pivotal data for investment decisions.

 
ASSETSCASH BALANCE (B)RECEIVABLES (M)OTHER REC. (M)INVENTORIES (M)OTHER CURRENT LIAB. (M)CURRENT ASSETS (B)TANGIBLE ASSETS (B)LONG-T. INVEST. (B)LONG-T. REC. (M)INTANGIBLE ASSETS (M)GOODWILL (B)OTHER NON-CURRENT ASSETS (M)NON-CURRENT ASSETS (B)TOTAL ASSETS (B)LIABILITIESCOMMON STOCK (k)ADDITIONAL PAID-IN CAPITAL (B)RETAINED EARNINGS (M)OTHER EQUITY (M)UNREAL. GAINS/LOSSES (M)EQUITY (B)LIABILITIES (M)PROVISIONS (M)OTHER SHORT-TERM LIAB. (M)SHORT-TERM DEBTS (M)LONG-TERM DEBT PORTION (B)SHORT-TERM REC. (B)LONG-T. LIAB. (B)DEFERRED TAXES (M)OTHER LIAB. (B)LONG-T. LIABILITIES (B)DEBT (B)TOTAL CAPITAL (B)
20162017201820192020202120222023
               
0.010.030.160.932.360.80.681.04
19.7428.6451.4657.51313.47423.01432.49394.55
22.84.46.7980.5189.6108.8972.9148.98
1.013.324.98.53164.75231.72326.03259.71
8.1913.8222.4614.17425.78419.22428.83191.36
0.070.080.241.093.351.981.942.03
0.020.030.070.160.741.721.941.65
0.010.080.210.630.921.251.051.15
03.693.375.4115.3816.126.435.25
0000469.46531.44476.06420.67
00001.852.162.162.16
3.193.297.8914.89808.43386.36359.1528.44
0.040.120.290.84.86.065.985.42
0.10.20.531.98.158.047.927.45
               
120120164261323326326367
0.010.010.051.33.653.643.643.87
62.79139.05204.03478.23-225.4160.86-296.68-1.19
0000.23383.84349.87398.77-50.78
00000000
0.080.150.251.783.814.053.743.82
1.583.774.697.55295.7281.05326.13245.76
4.876.817.7720.99147.68105.85140.37133.35
9.213.8419.5119.43125.32300.96289.88195.72
012.11000006.91
0000.020.170.241.920.95
0.020.040.040.070.740.932.671.53
0000.022.82.420.910.95
003.128.16119.18117.7392.269.19
0.010.010.230.020.740.670.641.21
0.010.010.240.053.663.21.642.23
0.030.050.280.124.44.134.323.76
0.10.20.531.98.218.188.067.58
Details

Balance Sheet

ⓘ

Understanding the Balance Sheet

The balance sheet of VIVA Biotech Holdings provides a detailed financial snapshot, revealing the company's assets, liabilities, and equity at a specific point in time. Analyzing these components is crucial for investors looking to understand VIVA Biotech Holdings's financial health and stability.

Assets

VIVA Biotech Holdings's assets represent everything the company owns or controls that has monetary value. These are categorized into current and non-current assets, offering insights into the company's liquidity and long-term investments.

Liabilities

Liabilities are obligations that VIVA Biotech Holdings must settle in the future. Analyzing the ratio of liabilities to assets provides insights into the company's financial leverage and risk exposure.

Equity

Equity refers to the residual interest in the assets of VIVA Biotech Holdings after deducting liabilities. It represents the owners’ claim on the company’s assets and earnings.

Year-to-Year Analysis

Comparing balance sheet figures year-to-year allows investors to identify trends, growth patterns, and potential financial risks, facilitating informed investment decisions.

Interpreting the Data

Detailed analysis of assets, liabilities, and equity can provide investors with comprehensive insights into VIVA Biotech Holdings's financial standing, aiding in investment evaluations and risk assessments.

 
NET INCOME (M)DEPRECIATION (M)DEFERRED TAXES (M)CHANGES IN WORKING CAPITAL (M)NON-CASH ITEM (M)PAID INTEREST (M)PAID TAXES (M)NET CASH FLOW FROM OPERATING ACTIVITIES (M)CAPITAL EXPENDITURES (M)CASH FLOW FROM INVESTING ACTIVITIES (M)CASH FLOW FROM OTHER INVESTING ACTIVITIES (M)INTEREST INCOME AND EXPENSES (M)NET DEBT CHANGE (B)NET CHANGE IN EQUITY (B)CASH FLOW FROM FINANCING ACTIVITIES (B)CASH FLOW FROM OTHER FINANCING ACTIVITIES ()TOTAL DIVIDENDS PAID (M)NET CHANGE IN CASH FLOW (B)FREE CASH FLOW (M)SHARE-BASED COMPENSATION (M)
2016201720182019202020212022
2886105280-356347-459
3593469153185
0000000
-10-16-25-20-90-306-98
0-47-78-248409-116758
0000117172
26416174580
212712463277386
-7-18-46-56-592-565-249
-19-9-69-290-3,838-868-372
-129-23-233-3,245-303-123
0000000
000-0.024.46-0.42-0.07
000.21.210.92-0.130
000.180.985.31-0.65-0.14
---19.00-76.00-17.00-84.00-70.00
000-135-51-160
00.020.130.751.4-1.51-0.12
13.788.97-34.79-10.18-560.46-487.35136.51
0000000

VIVA Biotech Holdings stock margins

The VIVA Biotech Holdings margin analysis displays the gross margin, EBIT margin, as well as the profit margin of VIVA Biotech Holdings. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for VIVA Biotech Holdings.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details

Margin

ⓘ

Understanding Gross Margin

The gross margin, expressed as a percentage, delineates the gross profit made from the VIVA Biotech Holdings's sales revenue. A higher gross margin percentage indicates that the VIVA Biotech Holdings retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.

EBIT Margin Analysis

EBIT margin represents the VIVA Biotech Holdings's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.

Revenue Margin Insights

The revenue margin demonstrates the VIVA Biotech Holdings's total revenue generated. When comparing the revenue margin year over year, investors can gauge the VIVA Biotech Holdings's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.

Interpreting Expectations

The expected values for gross, EBIT, and revenue margins provide future financial outlook of the VIVA Biotech Holdings. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.

Comparative Analysis

Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the VIVA Biotech Holdings's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.

VIVA Biotech Holdings Margin History

VIVA Biotech Holdings Gross marginVIVA Biotech Holdings Profit marginVIVA Biotech Holdings EBIT marginVIVA Biotech Holdings Profit margin
2025e34.26 %14.21 %15.17 %
2024e34.26 %13.28 %14.51 %
202334.26 %10.89 %-5.39 %
202234.28 %12.41 %-22.21 %
202130.94 %12.36 %13.67 %
202043.74 %12.84 %-55.51 %
201948.25 %18.61 %82.3 %
201850.21 %25.98 %43.11 %
201758.14 %38.74 %51.44 %
201656.11 %30.48 %25.36 %

VIVA Biotech Holdings Stock Sales Revenue, EBIT, Earnings per Share

The VIVA Biotech Holdings earnings per share therefore indicates how much revenue VIVA Biotech Holdings has generated per share in a given period. The earnings before interest and taxes per share shows how much of the operating profit corresponds to each share. The earnings per share indicates how much of the profit belongs to each share.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Sales per Share
EBIT per share
Earnings per Share
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue VIVA Biotech Holdings earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates VIVA Biotech Holdings's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of VIVA Biotech Holdings’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating VIVA Biotech Holdings's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

VIVA Biotech Holdings Revenue, EBIT and net profit per share

DateVIVA Biotech Holdings Sales per ShareVIVA Biotech Holdings EBIT per shareVIVA Biotech Holdings Earnings per Share
2025e1.6 undefined0 undefined0.24 undefined
2024e1.41 undefined0 undefined0.21 undefined
20231.11 undefined0.12 undefined-0.06 undefined
20221.24 undefined0.15 undefined-0.28 undefined
20211.07 undefined0.13 undefined0.15 undefined
20200.44 undefined0.06 undefined-0.25 undefined
20190.22 undefined0.04 undefined0.18 undefined
20180.18 undefined0.05 undefined0.08 undefined
20170.13 undefined0.05 undefined0.07 undefined
20160.08 undefined0.03 undefined0.02 undefined

VIVA Biotech Holdings business model

VIVA Biotech Holdings is a Chinese company specializing in the development of pharmaceuticals. It was listed on the Hong Kong Stock Exchange in 2018 and is headquartered in Shanghai. The company started as a small start-up in 2013 but has quickly become one of the industry leaders in pharmaceutical discovery and development. VIVA Biotech Holdings' business model revolves around creating a shared ecosystem for biotechnology start-ups and their customers. The company offers a wide range of services, including target molecule identification and validation, drug candidate optimization, and speeding up the timeline for clinical trials and commercialization. One key aspect of VIVA Biotech Holdings' business model is its VIVA Accelerator programs, which support and foster promising early-stage biotechnology start-ups. These programs provide start-ups with access to state-of-the-art facilities, expert advice, and funding opportunities. The company also operates several divisions focused on the discovery and development of new pharmaceuticals. These divisions include drug candidate synthesis, screening platforms for identifying drug candidates, and structural elucidation of proteins and other molecules. A major focus of VIVA Biotech Holdings is the development of cancer treatments. The company has developed a wide range of drug candidates that specifically target and destroy cancer cells. This includes both small molecules and biological drugs. In addition to cancer research, VIVA Biotech Holdings is also involved in the discovery and development of drugs for other diseases such as inflammatory and metabolic disorders. The company works closely with its customers and partners to develop targeted treatment options. Overall, VIVA Biotech Holdings has achieved an impressive track record in drug discovery and development in recent years. The company has developed a wide range of drug candidates at various stages of clinical development that have the potential to revolutionize the treatment of cancer and other diseases. As a company, VIVA Biotech Holdings is also committed to promoting the biotechnology sector and supporting start-ups and young companies. It is an important player in the Chinese biotech industry and an emerging company in the global pharmaceutical development market. VIVA Biotech Holdings is one of the most popular companies on Eulerpool.com.

VIVA Biotech Holdings SWOT Analysis

Strengths

VIVA Biotech Holdings has a strong track record in the biotech industry, consistently delivering innovative solutions and high-quality services to its clients.

The company boasts a state-of-the-art infrastructure and well-equipped laboratories, enabling efficient and timely execution of projects.

VIVA Biotech Holdings has a highly skilled and experienced team of scientists and researchers who have expertise in various disciplines, enhancing the company's overall capabilities.

Weaknesses

One of the weaknesses of VIVA Biotech Holdings is its heavy dependence on a few key clients for a significant portion of its revenue, which exposes the company to potential financial risks if there are any disruptions in those client relationships.

The rapid pace of technological advancements in the biotech industry poses a challenge for VIVA Biotech Holdings to consistently stay up-to-date and invest in the latest equipment and technologies.

The company may face challenges in retaining top talent and attracting new skilled professionals, due to the competitive nature of the biotech market.

Opportunities

The biotech industry is experiencing significant growth worldwide, driven by increased demand for personalized medicine and advancements in genetic research. This presents VIVA Biotech Holdings with ample opportunities to expand its client base and explore new markets.

VIVA Biotech Holdings can capitalize on the rising trend of outsourcing in the biotech sector, as more companies look to partner with specialized service providers to reduce costs and enhance efficiency.

The company can leverage its strong reputation and expertise to forge strategic partnerships and collaborations with leading pharmaceutical companies and academic institutions, opening doors for joint research projects and mutually beneficial ventures.

Threats

Intense competition within the biotech industry poses a threat to VIVA Biotech Holdings, as new entrants and established competitors vie for market share and clients.

Legal and regulatory uncertainties in the biotech sector can impact the operations and growth prospects of VIVA Biotech Holdings, requiring the company to stay vigilant and adapt to changing compliance requirements.

Emerging technologies or breakthrough inventions in the biotech field could disrupt the existing business models and services offered by VIVA Biotech Holdings, necessitating constant innovation and adaptation.

VIVA Biotech Holdings Eulerpool Fair Value

Details

Fair Value

ⓘ

Understanding Fair Value

The fair value of a stock provides insights into whether the stock is currently undervalued or overvalued. It is calculated based on profit, revenue, or dividends and offers a comprehensive perspective of the stock’s intrinsic value.

Income-Based Fair Value

This is calculated by multiplying the earnings per share by the average P/E ratio of the selected past years for smoothing. If the fair value is higher than the current market price, it suggests that the stock is undervalued.

Example 2022

Fair Value Profit 2022 = Earnings per Share 2022 / Average P/E Ratio 2019 - 2021 (3 Years Smoothing)

Revenue-Based Fair Value

It is derived by multiplying the revenue per share by the average price-to-sales ratio of the selected past years for smoothing. An undervalued stock is identified if the fair value exceeds the ongoing market price.

Example 2022

Fair Value Revenue 2022 = Revenue per Share 2022 / Average PSR 2019 - 2021 (3 Years Smoothing)

Dividend-Based Fair Value

This value is determined by dividing the dividend per share by the average dividend yield of the selected past years for smoothing. A higher fair value than the market price indicates an undervalued stock.

Example 2022

Fair Value Dividend 2022 = Dividend per Share 2022 * Average Dividend Yield 2019 - 2021 (3 Years Smoothing)

Expectations and Forecasts

Future expectations provide potential trajectories for stock prices and aid investors in decision-making. The expected values are forecasted figures of fair value, taking into account the growth or decline trends of profit, revenue, or dividend.

Comparative Analysis

Comparing the fair value based on profit, revenue, and dividend provides a holistic overview of the stock’s financial health. Observing the annual and per-annual variations contributes to understanding the consistency and reliability of stock performance.

VIVA Biotech Holdings historical P/E ratio, EBIT multiple, and P/S ratio

VIVA Biotech Holdings shares outstanding

The number of shares was VIVA Biotech Holdings in 2023 — This indicates how many shares 1.94 B is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Number of stocks
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue VIVA Biotech Holdings earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates VIVA Biotech Holdings's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of VIVA Biotech Holdings’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating VIVA Biotech Holdings's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

VIVA Biotech Holdings dividend history and estimates

In 2023, VIVA Biotech Holdings paid a dividend amounting to 0 CNY. Dividend means that VIVA Biotech Holdings distributes a portion of its profits to its owners.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Dividend
Dividend (Estimate)
Details

Dividend

ⓘ

Dividend Overview

The dividend per year chart for VIVA Biotech Holdings provides a comprehensive view of the annual dividends distributed to shareholders. Analyze the trend to understand the consistency and growth in dividend payouts over the years.

Interpretation and Use

A consistent or increasing trend in dividends can indicate the company's profitability and financial health. Investors can use this data to identify VIVA Biotech Holdings’s potential for long-term investment and income generation through dividends.

Investment Strategy

Incorporate the dividend data in evaluating VIVA Biotech Holdings's overall performance. A thorough analysis, considering other financial aspects, will help in making informed investment decisions for optimal capital growth and income generation.

VIVA Biotech Holdings Dividend History

DateVIVA Biotech Holdings Dividend
20210.01 undefined
20200.03 undefined
20190.01 undefined

VIVA Biotech Holdings dividend payout ratio

In 2023, VIVA Biotech Holdings had a payout ratio of 4.97%. The payout ratio indicates the percentage of the company's profits that VIVA Biotech Holdings distributes as dividends.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Payout ratio
Details

Payout ratio

ⓘ

What is Yearly Payout Ratio?

The yearly payout ratio for VIVA Biotech Holdings represents the proportion of earnings paid out as dividends to shareholders. It is an indicator of the company's financial health and stability, illustrating how much profit is being returned to investors versus being reinvested back into the company.

How to Interpret the Data

A lower payout ratio for VIVA Biotech Holdings could mean that the company is reinvesting more into its growth, whereas a higher ratio indicates more earnings are being distributed as dividends. Investors seeking regular income might prefer companies with a higher payout ratio, while those looking for growth may opt for companies with a lower ratio.

Using the Data for Investments

Evaluate VIVA Biotech Holdings's payout ratio in conjunction with other financial metrics and performance indicators. A sustainable payout ratio, coupled with strong financial health, can indicate a reliable dividend payout. However, a very high ratio might suggest the company is not sufficiently reinvesting in its future growth.

VIVA Biotech Holdings Payout Ratio History

DateVIVA Biotech Holdings Payout ratio
2025e5.21 %
2024e5.69 %
20234.97 %
20224.97 %
20217.14 %
2020-13 %
20192.79 %
20184.97 %
20174.97 %
20164.97 %

The World’s Best Investors Are On Eulerpool

Unfortunately, there are currently no price targets and forecasts available for VIVA Biotech Holdings.

Eulerpool ESG Scorecard© for the VIVA Biotech Holdings stock

Eulerpool World ESG Rating (EESG©)

74/ 100

🌱 Environment

83

👫 Social

70

🏛️ Governance

69

Environment

Scope 1 - Direct Emissions
1,404.35
Scope 2 - Indirect emissions from purchased energy
45,376.9
Scope 3 - Indirect emissions within the value chain
Total CO₂ emissions
46,781.2
CO₂ reduction strategy
Coal energy
Nuclear power
Animal experiments
Fur & Leather
Pesticides
Palm Oil
Tobacco
Genetically modified organisms
Climate concept
Sustainable forestry
Recycling regulations
Environmentally friendly packaging
Hazardous substances
Fuel consumption and efficiency
Water consumption and efficiency

Social

Percentage of female employees45.02
Percentage of women in management
Percentage of Asian employees
Share of Asian management
Percentage of Hispanic/Latino employees
Hispano/Latino Management share
Percentage of Black employees
Black Management Share
Percentage of white employees
White Management Share
Adult content
Alcohol
Weapons
Firearms
Gambling
Military contracts
Human rights concept
Privacy concept
Occupational health and safety
Catholic

Governance (Corporate Governance)

Environmental reporting
Stakeholder Engagement
Call Back Policies
Antitrust law

The Eulerpool ESG Scorecard© is the strictly copyrighted intellectual property of Eulerpool Research Systems. Any unauthorized use, imitation, or infringement will be actively pursued and may lead to significant legal consequences. For licenses, collaborations, or usage rights, please contact us directly via our contact form. Contact Form to us.

VIVA Biotech Holdings shareholders

%
Name
Stocks
Change
Date
16.67049 % Mao (Chen Cheney)357,043,52706/3/2024
10.22678 % Wu (John Jiong)219,034,09201/5/2024
7.00355 % Temasek Holdings Pte. Ltd.150,000,000012/31/2023
6.11913 % Mao (Jun)131,057,65406/3/2024
4.66904 % Zhou (Min)100,000,00006/3/2024
3.96868 % Wang (Stephen Hui)85,000,00003/6/2024
0.99834 % Wu (Ying)21,382,127012/31/2023
0.69196 % Ren (Delin)14,820,248012/31/2023
0.55253 % Dimensional Fund Advisors, L.P.11,834,00009/30/2024
0.13490 % Norges Bank Investment Management (NBIM)2,889,337-372,8866/30/2024
1
2
3
4
...
5

VIVA Biotech Holdings Executives and Management Board

Mr. Delin Ren(63)
VIVA Biotech Holdings Executive Director (since 2018)
Compensation 3.72 M
Mr. Ying Wu(60)
VIVA Biotech Holdings Executive Vice President, Executive Director (since 2009)
Compensation 3.07 M
Mr. Chen Cheney Mao(61)
VIVA Biotech Holdings Executive Chairman of the Board, Chief Executive Officer (since 2018)
Compensation 2.76 M
Dr. Lei Fu(60)
VIVA Biotech Holdings Non-Executive Independent Director
Compensation 216,000
Ms. Xiangrong Li(50)
VIVA Biotech Holdings Non-Executive Independent Director
Compensation 216,000
1
2
3
4

VIVA Biotech Holdings Supply Chain

NameRelationshipTwo-week correlationOne-month correlationThree-Month CorrelationSix-Month CorrelationOne Year CorrelationTwo-Year Correlation
HBM Holdings Stock
HBM Holdings
SupplierCustomer0,740,710,170,930,87
JPMorgan Chase Stock
JPMorgan Chase
SupplierCustomer0,640,740,760,890,54-0,28
Schrodinger Stock
Schrodinger
SupplierCustomer0,550,780,840,560,940,72
1

Most common questions regarding VIVA Biotech Holdings

What values and corporate philosophy does VIVA Biotech Holdings represent?

VIVA Biotech Holdings represents a commitment to innovation, collaboration, and excellence in the biotechnology industry. As a leading company, VIVA strives to provide high-quality drug discovery services and help clients achieve their research goals. The company's corporate philosophy revolves around customer-centric solutions, where their experienced team utilizes cutting-edge technologies and state-of-the-art facilities to deliver best-in-class services. With a focus on rapid and cost-effective drug development, VIVA Biotech Holdings aims to contribute extensively to the advancement of healthcare and pharmaceutical breakthroughs.

In which countries and regions is VIVA Biotech Holdings primarily present?

VIVA Biotech Holdings is primarily present in China and the United States.

What significant milestones has the company VIVA Biotech Holdings achieved?

VIVA Biotech Holdings has achieved several significant milestones. Firstly, the company successfully listed on the Hong Kong Stock Exchange in 2019, marking an important step in its growth. Additionally, VIVA Biotech has consistently demonstrated its strength in drug discovery services and collaborations. It has established numerous strategic partnerships with leading pharmaceutical companies globally, fueling its reputation as a trusted biotech partner. Moreover, VIVA Biotech has expanded its operations by opening multiple state-of-the-art research centers in China and abroad. These accomplishments highlight VIVA Biotech Holdings' continuous commitment to innovation, partnerships, and global expansion within the biotech industry.

What is the history and background of the company VIVA Biotech Holdings?

VIVA Biotech Holdings is a leading structure-based drug discovery platform established in 2008. The company primarily focuses on enabling and supporting biotechnology and pharmaceutical companies in their drug discovery and development efforts. VIVA Biotech Holdings has a proven track record of success in assisting clients to identify and optimize potential drug candidates. Through its innovative services and expertise, the company has built a strong reputation and has become a trusted partner in the biotech industry. With a commitment to scientific excellence and cutting-edge technology, VIVA Biotech Holdings continues to contribute to advancements in drug discovery, making valuable contributions to the healthcare sector.

Who are the main competitors of VIVA Biotech Holdings in the market?

Some of the main competitors of VIVA Biotech Holdings in the market include Charles River Laboratories, Evotec AG, WuXi AppTec, Eurofins Scientific, and Albany Molecular Research Inc.

In which industries is VIVA Biotech Holdings primarily active?

VIVA Biotech Holdings is primarily active in the biotechnology and pharmaceutical industries.

What is the business model of VIVA Biotech Holdings?

The business model of VIVA Biotech Holdings focuses on providing comprehensive and high-quality drug discovery services to global pharmaceutical and biotechnology companies. VIVA Biotech offers structure-guided drug discovery (SGDD) and other innovative technologies to accelerate the development of potential therapeutics. By leveraging its advanced platform and expertise, VIVA Biotech aims to identify and optimize drug candidates with high success rates. With a strong emphasis on collaboration and efficient processes, the company strives to facilitate the discovery and development of novel drugs, ultimately contributing to advancements in the healthcare industry.

What is the P/E ratio of VIVA Biotech Holdings 2024?

The VIVA Biotech Holdings P/E ratio is 3.77.

What is the P/S ratio of VIVA Biotech Holdings 2024?

The VIVA Biotech Holdings P/S ratio is 0.55.

What is the Quality Investing of VIVA Biotech Holdings?

The Quality Investing for VIVA Biotech Holdings is 4/10.

What is the revenue of VIVA Biotech Holdings 2024?

The expected VIVA Biotech Holdings revenue is 3.03 B CNY.

How high is the profit of VIVA Biotech Holdings 2024?

The expected VIVA Biotech Holdings profit is 439.11 M CNY.

What is the business model of VIVA Biotech Holdings

VIVA Biotech Holdings is a leading biopharmaceutical company offering a comprehensive range of top-quality services and advanced research tools. The company provides a wide range of solutions to support research and development projects in the field of biology, particularly in the areas of biochemistry, biotechnology, and drug development. The business model of VIVA Biotech Holdings is based on three main divisions: Viva Biotech, Viva Biotech Hutchison, and VivaBioCell. Viva Biotech is a leading service provider for drug discovery and development. The company offers comprehensive biological research services to accelerate drug development, with a focus on the rapid identification of high-quality drug candidates through the use of cutting-edge technology platforms and instruments. Viva Biotech Hutchison is a strategic partnership between the company and Hutchison China MediTech Limited, a leading Chinese biopharmaceutical company. The partnership includes a unique platform for drug discovery and development, securing access to proprietary technologies and instruments. The collaboration enables VIVA Biotech to offer a comprehensive and competitive value chain in drug development. The third division, VivaBioCell, is a specialized laboratory offering primary and cultured human cells. These cells are used in research to understand bioprocesses and develop innovative approaches to treating serious diseases. VivaBioCell enables the provision of high-quality cells in the shortest possible time, providing a competitive advantage. VIVA Biotech Holdings' portfolio includes a wide range of products and services, ranging from chemical molecule modeling to the manufacture of drug candidates. The offerings also include advanced screening approaches, protein production, structural elucidation, in vitro screening, and in vivo animal testing. Viva Biotech's biological research services utilize state-of-the-art technology platforms such as high-throughput screening, protein structural elucidation, and single-cell technology. The company has a network of over 600 customers, including biotechnology and pharmaceutical companies, as well as research institutions in North America, Europe, and Asia. The versatile and scientifically sound expertise of VIVA Biotech Holdings enables the company to develop tailored solutions for customer projects to achieve optimal results. In addition, VIVA Biotech Holdings has its own portfolio of selected drug candidates with potential for clinical success, which are sought after in the pharmaceutical industry. The portfolio consists of eight drug candidates, including two in Phase III clinical trials. VIVA Biotech Holdings' business model is based on extensive biological expertise, cutting-edge technology platforms, and a wide range of products and services to support biology research and development projects. The company specializes in the accelerated discovery of high-quality drug candidates, providing a competitive advantage over other companies in the market.

What is the VIVA Biotech Holdings dividend?

VIVA Biotech Holdings pays a dividend of 0 CNY distributed over payouts per year.

How often does VIVA Biotech Holdings pay dividends?

The dividend cannot currently be calculated for VIVA Biotech Holdings or the company does not pay out a dividend.

What is the VIVA Biotech Holdings ISIN?

The ISIN of VIVA Biotech Holdings is KYG9390W1015.

What is the VIVA Biotech Holdings WKN?

The WKN of VIVA Biotech Holdings is A2PH5Q.

What is the VIVA Biotech Holdings ticker?

The ticker of VIVA Biotech Holdings is 1873.HK.

How much dividend does VIVA Biotech Holdings pay?

Over the past 12 months, VIVA Biotech Holdings paid a dividend of 0.01 CNY . This corresponds to a dividend yield of about 1.17 %. For the coming 12 months, VIVA Biotech Holdings is expected to pay a dividend of 0 CNY.

What is the dividend yield of VIVA Biotech Holdings?

The current dividend yield of VIVA Biotech Holdings is 1.17 %.

When does VIVA Biotech Holdings pay dividends?

VIVA Biotech Holdings pays a quarterly dividend. This is distributed in the months of October, July, October, July.

How secure is the dividend of VIVA Biotech Holdings?

VIVA Biotech Holdings paid dividends every year for the past 2 years.

What is the dividend of VIVA Biotech Holdings?

For the upcoming 12 months, dividends amounting to 0 CNY are expected. This corresponds to a dividend yield of 0 %.

In which sector is VIVA Biotech Holdings located?

VIVA Biotech Holdings is assigned to the 'Health' sector.

Wann musste ich die Aktien von VIVA Biotech Holdings kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of VIVA Biotech Holdings from 7/9/2021 amounting to 0.01 CNY, you needed to have the stock in your portfolio before the ex-date on 6/16/2021.

When did VIVA Biotech Holdings pay the last dividend?

The last dividend was paid out on 7/9/2021.

What was the dividend of VIVA Biotech Holdings in the year 2023?

In the year 2023, VIVA Biotech Holdings distributed 0 CNY as dividends.

In which currency does VIVA Biotech Holdings pay out the dividend?

The dividends of VIVA Biotech Holdings are distributed in CNY.

All fundamentals about VIVA Biotech Holdings

Our stock analysis for VIVA Biotech Holdings Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of VIVA Biotech Holdings Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.